 |
 |
||
 |
 |
 |
|
|
|
 |
Kineret® is a medicine that is used to reduce the pain and swelling
associated with moderate to severe active rheumatoid arthritis. Kineret®
is a man-made protein that is similar to a naturally occurring protein called interleukin-1
receptor antagonist (IL-1ra) found in the body. Kineret® is for use by patients
eighteen years of age or older and for patients who have not responded to treatment with other
agents called disease-modifying antirheumatic drugs or DMARDS. Kineret® can be
used by itself or in combination with DMARDS. Kineret® should not be used with
medicines called Tumor Necrosis Factor (TNF) blocking agents such as ENBREL®
(etanercept), Humira™ (adalimumab), or Remicade® (infliximab). Kineret® has been associated with an increased incidence of serious infections (2%) vs. placebo (< 1%). Kineret® should be discontinued if a patient develops an infection, however most patients can continue taking Kineret® after their infection resolves. Kineret® should not be initiated in patients with active infections. Kineret® should not be used with TNF-blocking agents such as etanercept, adalimumab, and infliximab. A 7% rate of serious infections was observed in a 24-week study of concurrent administration of Kineret® and etanercept. Kineret® is contraindicated in patients with known hypersensitivity to E coli-derived proteins, Kineret®, or any components of the product. Percent of RA Patients Reporting Adverse Events with a Frequency of ≥ 5% In Kineret®-treated Patients Over a 6-month Period in Clinical Trials
Adverse events included those that were observed for patients in 2 clinical trials of Kineret® who received 100mg/day fixed dose. Patients in one study (N = 899) were on stable doses of methotrexate. Patients in the second study (N = 1399) included those who were on a variety of RA medications including some DMARD therapies and those who were DMARD-free. The most common side effect of Kineret® in clinical trials was injection site reaction (ISR) which was usually mild, characterized by redness, swelling, and pain, and lasted for 14 to 28 days. The development of ISRs in patients who had not previously experienced them was uncommon after the first month of therapy. View full Kineret® patient product information page. |
|||||||||||||||||||||||||||||||||||||
|
RHEUMATOID ARTHRITIS KINERET® AND RHEUMATOID ARTHRITIS DIET & EXERCISE REIMBURSEMENT IMPORTANT PRODUCT SAFETY INFORMATION |
||||||||||||||||||||||||||||||||||||||
